ABSTRACT
Objective: To study, analyse and compare the pharamacological efficacy of sitagliptin and metfromin in terms of blood glucose and glycated HbA1 in type 2 diaebtic (T2DM) subjects.
Methodology: An observational study was conducted at the Suleman Roshan Medical College from March 2019 to February 2020. A sample of 200 diagnosed cases of type 2 DM, divided into 100 sitaglitin and 100 metformin, was selected according to inclusion criteria. Sample was selected by non-probability convenient sampling. After 12 weeks therapy, the blood samples were taken, centrifuged and sera for biochemcial analysis. Fasting (FBG) and random blood glucose (RBG) and glycated HbA1 (HbA1c) were estimated by standard methods. Data was analyzed on SPSS (ver. 21.0) at 95% CI (P≤0.05).
Results: Age of Sitagliptin group was 50.5±11.5 comapred Metformin group 50.1±15.5 years (P=0.07). FBG in sitagliptin was decreased by 46% vs. 37% in metformin; RBG in sitagliptin was decreased by 90% vs. 69% in metformin and HbA1c decreased by 14.35 in sitagliptin vs. 11.4% in metformin. Nausea, vomiting, diarrhoea and headache was noted in 3%, 3%, 6% and 5% of those taking sitagliptin compared to 19%, 5%, 13% and 11% in metformin treated subjects respectively (P
Key words: Sitagliptin, metformin, glycemic control, type 2 diabetics.
|
